ATAI and IntelGenx enter into Feasibility Agreement to develop pharmaceutical-grade polymeric film technologies for delivery of psychedelic medicines

August 20, 2020 Articles 7:21 pm

Today, ATAI Life Sciences (“ATAI” or the “Company”), a global biotech developing psychedelic and non-psychedelic compounds for a variety of mental health indications, announced a Feasibility Agreement with IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (“IntelGenx”) for the development of novel formulations of pharmaceutical-grade psychedelics based on IntelGenx’s polymeric film technologies.

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on ATAI and innovations in the space.

Email
submit